Pfizer Declares First-Quarter 2023 Dividend
09 Dezembro 2022 - 1:15PM
Business Wire
Board of Directors approves increase in
quarterly cash dividend to $0.41 per share
Pfizer Inc. (NYSE: PFE) today announced that its board of
directors declared an increase in the quarterly cash dividend on
the company’s common stock to $0.41 for the first-quarter 2023
dividend, payable March 3, 2023, to holders of the Common Stock of
record at the close of business on January 27, 2023. The
first-quarter 2023 cash dividend will be the 337th consecutive
quarterly dividend paid by Pfizer.
“Our ability to increase our dividend is a testament to our
solid financial performance during 2022,” said Dr. Albert Bourla,
Pfizer Chairman and Chief Executive Officer. “This increase
reinforces Pfizer’s commitment of returning value to our
shareholders.”
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
more than 170 years, we have worked to make a difference for all
who rely on us. We routinely post information that may be important
to investors on our website at www.Pfizer.com. In addition, to
learn more, please visit us on www.Pfizer.com and follow us on
Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us
on Facebook at Facebook.com/Pfizer.
Category: Finance
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221208006035/en/
Media: PfizerMediaRelations@Pfizer.com +1 (212) 733-1226
Investor Contact: IR@Pfizer.com +1 (212) 733-4848
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024